Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Investor Presentation (September 2017)
18 slides from Optiscan Imaging's investor presentation, September 2017
Slide 1: Optiscan Imaging Ltd Investor Presentation - September 2017
Optiscan Imaging Ltd Investor Presentation - September 2017
Slide 2: Disclaimer
Disclaimer Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are
Slide 3: Background
Background • Based in Melbourne, Australia, Optiscan are a global leader in live micro imaging through its unique patented clinical confocal laser endomicroscopy technology, providing surgeons with real time visualisation of a human cell during a surgical procedure. • Optiscan is focused on commerci
Slide 4: Investment Highlights
Investment Highlights Proven Technology - 1st generation technology was licensed to Pentax for a licencing fee of Approx. USD20m and achieved reimbursement status in USA. 2nd Generation Device - 70% smaller and yields full HD (2.1 Megapixels) across a variable field with interactive depth control. L
Slide 5: Corporate Structure
Corporate Structure Number of % of fully 12 Month Share Price Performance and Volume Capital Structure Units (m) diluted Ordinary Shares, ASX Code OIL 377.1 93.9% Unlisted Options 24.5 6.3% Fully Diluted Shares* 401.6 100% Market Cap and Liquidity Current Market Cap (as at 26 Sept 2017) A$31.3 milli
Slide 6: Board and Management
Board and Management Alan Hoffman • 20 years’ experience in executive management roles in organisations such as Shell Australia, the Wesfarmers Group and the Coventry Group. Chairman • Commercially astute and strategically focused, Alan’s leadership will drive performance improvement of Optiscan as
Slide 7: The Coming Medical Revolution that is Confocal Laser Endomicroscopy
The Coming Medical Revolution that is Confocal Laser Endomicroscopy • Having invented the confocal laser microscope (CLE), Optiscan then set about miniaturising this technology so it can be practically used for in vivo clinical use, inside the human body. • A tiny scanner attached to a single optica
Slide 8: Endoscopic Process and Medical Need
Endoscopic Process and Medical Need • Common endoscopic procedures involve 3 key steps: 1. Detection of an area of interest 2. Characterisation (i.e. a closer look) 3. Confirmation – a firm cellular diagnosis • Cleansing • Magnifying • High Resolution Endoscopy • Conventional • High Definition • Chr
Slide 9: Endomicroscopy Workflow
Endomicroscopy Workflow Conventional endoscopic Optiscan’s endomicroscope view provides detection of scanner provides fast scanning areas of interest and initial and ultra-high definition “digital characterisation biopsy” 1? Conventional methods cannot identify the cancerous areas 2? Optiscan Imagin
Slide 10: Competitive Advantage
Competitive Advantage Compared to Optiscan’s technology, existing technologies have the following disadvantages: • 60 fold lower image information content. • Lower resolution. • Maximum 30,000 optical pixels (0.03 Megapixels), only a few thousand pixels for smaller probes. • There are gaps between f
Slide 11: Market Opportunities
Market Opportunities • Optiscan’s platform technology is applicable in any field of endoscopy/surgery with strong clinical evidence already proving its effectiveness in several fields • Gastrointestinal Endoscopy in particular poses as a large opportunity for Optiscan with up to 14m procedures in th
Slide 12: Neurosurgery – Initial Commercialisation Focus
Neurosurgery – Initial Commercialisation Focus CZM are initially targeting the neurosurgery market due the immense precision required when conducting this type of surgery. Unlike cutting out cancer in other places (bowel, breast or skin), cutting a millimetre into normal brain tissue can leave the p
Slide 13: Neurosurgery – Optiscan Solution
Neurosurgery – Optiscan Solution • The microscope magnification can come down to subcellular level with the images beamed directly to the pathologist screen, monitor or tablet. • The surgeon uses the Optiscan “Digital Biopsy” probe technology to move across the tissue which allows them to clearly id
Slide 14: Optical Sectioning Feature
Optical Sectioning Feature Optiscan technology delivers interactive optical sectioning Optiscan Imaging Ltd Investor Presentation – September 2017
Slide 15: Surface to Subsurface Cellular Imaging
Surface to Subsurface Cellular Imaging Automated Z-Stack and 3D Visualisation Z-Stack Sequence 3D animation Optiscan Imaging Ltd Investor Presentation – September 2017
Slide 16: Carl Zeiss Meditec
Carl Zeiss Meditec In 2007, Optiscan signed a collaboration deal with major German optics CZM. The agreement gives CZM exclusive use of Optician’s technology for clinical rigid endo-microscope applications in the (CZM) core segments. • CZM FY16 revenue €1.09bn, EBIT €154m • Major German optics compa
Slide 17: Carl Zeiss Meditec - Partnership
Carl Zeiss Meditec - Partnership Optiscan have recently shipped pilot devices to CZM that have been placed in the hands of some of the worlds leading surgeons throughout Europe and the USA. • CZM are a multinational dominant company with significant resources, credibility with all stakeholders, exte
Slide 18: ViewnVivo
ViewnVivo ViewnVivo is a miniaturised fluorescence endomicroscope platform that brings the next generation of Optiscan’s incredible imaging capability and flexibility for Preclinical Research. • Launched in late 2016, ViewnVivo provides the same underlying imaging technology as that used in CZM coll
Optiscan Imaging — Investor Presentation (September 2017) on 6ix